Arbutus Biopharma (($ABUS)) announced an update on their ongoing clinical study. Arbutus Biopharma is conducting a long-term follow-up study ...

Moderna stock fell 11% on Wednesday after the vaccine maker lost a patent fight against Arbutus Biopharma. Arbutus jumped 103% following the ruling as it could lead to royalty payments from Moderna.

Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for ...

Roivant Sciences and Moderna Therapeutics, two of the most highly-funded and controversial companies in the biotechnology world, are headed for a collision course over medical technology. On Monday, ...

(Reuters) -Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus ...

It’s a David-and-Goliath fight between two unprofitable startups. Moderna Therapeutics is valued by its private investors at $5 billion, as it promises to create a new kind of medicine that will turn ...

Hillary Tully, Arbutus Folk School’s new executive director, has big plans to expand both the kind of arts the school teaches and community access to the offerings. For the moment, though, Tully is ...